EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU
Decision by the EC is expected in the third quarter of 2017
Not intended for UK-based media
DARMSTADT, Germany and NEW YO... Biopharmaceuticals, Oncology, Regulatory Merck KGaA, BAVENCIO, avelumab, metastatic Merkel cell carcinoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Germany Health | Immunotherapy | Merck | Merkel Cell Carcinoma | Pharmaceuticals | Skin | Skin Cancer